As official media partners, VJHemOnc is excited to bring you the latest news from the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), which was held virtually from 14-17 of March, 2021.

View all videos

EBMT 2021

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
14–17 March 2021 | Virtual Meeting

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Load More...

EBMT 2021

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
14–17 March 2021 | Virtual Meeting

As official media partners, VJHemOnc is excited to bring you the latest news from the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), which was held virtually from 14-17 of March, 2021.

View all videos

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter